ออฟไลน์ด้วยแอป Player FM !
AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and CV Outcomes in Patients with CKD
ซีรีส์ที่ถูกเก็บถาวร ("ฟีดที่ไม่ได้ใช้งาน" status)
When? This feed was archived on June 01, 2023 17:14 (). Last successful fetch was on April 25, 2023 16:40 ()
Why? ฟีดที่ไม่ได้ใช้งาน status. เซิร์ฟเวอร์ของเราไม่สามารถดึงฟีดพอดคาสท์ที่ใช้งานได้สักระยะหนึ่ง
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 352750137 series 1802332
Patients with chronic kidney disease are at high risk of worsening kidney disease and cardiovascular events. Treatments that can slow down the worsening of kidney disease and reduce the need for dialysis and kidney transplants and the risk of cardiovascular events are potentially of great importance. While diabetes remains the biggest cause of chronic kidney disease, over half of patients with chronic kidney disease do not have diabetes, so treatments that work in people with and without diabetes are key.
In this interview, David Preiss MBChB, MRCP, FRCPath, PhD and Cindy L. Grines MD, FACC, MSCAI discuss AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and Cardiovascular Outcomes in Patients with CKD.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
101 ตอน
AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and CV Outcomes in Patients with CKD
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ซีรีส์ที่ถูกเก็บถาวร ("ฟีดที่ไม่ได้ใช้งาน" status)
When? This feed was archived on June 01, 2023 17:14 (). Last successful fetch was on April 25, 2023 16:40 ()
Why? ฟีดที่ไม่ได้ใช้งาน status. เซิร์ฟเวอร์ของเราไม่สามารถดึงฟีดพอดคาสท์ที่ใช้งานได้สักระยะหนึ่ง
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 352750137 series 1802332
Patients with chronic kidney disease are at high risk of worsening kidney disease and cardiovascular events. Treatments that can slow down the worsening of kidney disease and reduce the need for dialysis and kidney transplants and the risk of cardiovascular events are potentially of great importance. While diabetes remains the biggest cause of chronic kidney disease, over half of patients with chronic kidney disease do not have diabetes, so treatments that work in people with and without diabetes are key.
In this interview, David Preiss MBChB, MRCP, FRCPath, PhD and Cindy L. Grines MD, FACC, MSCAI discuss AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and Cardiovascular Outcomes in Patients with CKD.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
101 ตอน
ทุกตอน
×ขอต้อนรับสู่ Player FM!
Player FM กำลังหาเว็บ